Comparative Pharmacology
Head-to-head clinical analysis: CUTIVATE versus MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUTIVATE versus MEDROL.
CUTIVATE vs MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression to inhibit inflammatory mediators, vasoconstriction, and immunosuppression.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines (e.g., IL-1, IL-2, TNF-alpha). It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Apply a thin layer to affected skin areas once or twice daily. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
4 to 48 mg orally once daily or every other day, depending on condition. Initial dose may be up to 48 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life); short half-life supports twice-daily dosing for maintenance of clinical effect.
Terminal half-life of methylprednisolone is 2.5-3.5 hours; for the active metabolite (prednisolone), half-life is 2.1-3.5 hours. Clinical context: Despite short half-life, pharmacodynamic effects persist beyond plasma presence due to receptor-mediated actions.
Primarily hepatic metabolism; metabolites are excreted renally and fecally. Unchanged drug is negligible in urine. Route: renal (~60% as metabolites), fecal (~40% as metabolites).
Renal (approximately 80-90% as metabolites, <5% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Corticosteroid
Corticosteroid